anayamalik, Author at European Medical Journal - Page 42 of 83

Transforming Clinical Trials to Fast-Track Cancer Immunotherapy

Discover how SITC’s innovative strategies are transforming clinical trials to accelerate the development and approval of cancer immunotherapies, aiming for 100 new treatments in the next decade.

To What Extent Can a Smartphone App Help Pregnant Smokers Quit?

A groundbreaking new study is testing an AI-powered smartphone app designed to help pregnant smokers quit, leveraging social support and adaptive reinforcement learning to improve outcomes.

Smarter Screening: Using AI To Identify TB Risk in HIV

A new machine learning model predicts active tuberculosis in people with HIV more accurately than current tests, offering a promising tool for early intervention and preventive treatment.

Adipose Stem Cells: Transforming Care in Systemic Sclerosis

Adipose-derived stem cells (ADSCs) may offer a groundbreaking new approach to treating systemic sclerosis (SSc), according to a recent study.

Blood Plasma in Wound Healing: Breakthrough or Hurdle?

Blood plasma, fibrinogen, and fibrin have long been explored for their role in skin tissue engineering and dermatological treatments, with promising preclinical results—but clinical adoption remains limited.

School-Based Rebound Therapy for Improved Chest Health in Children

A recent study explores the potential of school-based rebound therapy to improve chest health, motor function, and quality of life in children with neurodisability and respiratory issues.

Lower Breast Cancer Screening Rates Determined by Housing Status

Women experiencing housing insecurity are significantly less likely to receive routine breast cancer screening, according to a new study analyzing Medicaid beneficiaries in Pennsylvania.

PAP Therapy Lowers Death Risk in Sleep Apnea

A systematic review and meta-analysis has confirmed that positive airway pressure (PAP) therapy significantly reduces the risk of both all-cause and cardiovascular mortality in patients with obstructive sleep apnea (OSA).

Nintedanib May Slow Lung Function Decline in SSc-ILD

A recent analysis of the SENSCIS and SENSCIS-ON trials has demonstrated that nintedanib effectively slows the decline in forced vital capacity (FVC) among patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Hepatitis C Diagnostic Advances: New Review

A newly published review highlights the evolution of Hepatitis C Virus (HCV) diagnostics, detailing key technological breakthroughs that have improved detection and management.